The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.

but some believe that the acquisition will pay off for the big pharma company. It needs new products to succeed its flagship product, Humira, which will face biosimilar competition in the near future.

Companies like Zai Labs (NASDAQ:ZLAB), AstraZeneca's (NASDAQ:AZN) Gracell or Coherus Biosicences (NASDAQ:CHRS), which closely ...

Big pharmaceutical companies may have developed a strategy to block out competition to their prescription drugs. A recent study by researchers at the Yale School of Management and London Business ...

For instance, while it seems likely that Amazon could get involved in selling and shipping drugs or medical equipment, it's unclear what impact it could have on the big pharmaceutical companies ...